| April 9th, 2026 | |
|---|---|
| 7:30 AM | Registration |
| 8:00 AM | Welcome & Opening Remarks · Raquel Sánchez-Valle. Hospital Clínic de Barcelona. IDIPABS; Barcelona, Spain · Juan Fortea. Hospital of Sant Pau; Barcelona, Spain · Arcadi Navarro. Fundació Pasqual Maragall, Hub Alzheimer Barcelona, Spain · Alberto Lleó. Hospital of Sant Pau; Barcelona, Spain · Sid O’Bryant. UNT Health Fort Worth (ITR); Texas, USA · Maria Carrillo. Alzheimer’s Association; Chigaco, USA |
| 8:30 AM | Oral Session 1. Basic Science Moderators: Heather Snyder and Alberto Lleó 1. Characterization of Copathologies In APOEε4 Homozygotes Iñigo Rodríguez-Baz. Hospital of Sant Pau; Barcelona, Spain 2. Neuropathologic Correlates of Cognitive Resilience to Alzheimer’S Disease In Down Syndrome Lisi Flores-Aguilar. University of California; Irvine, USA 3. Potential Convergent Inflammatory and Vascular Drivers Of Tau Pathology And Clinical Progression In Adults With Down Syndrome Natalie Edwards. Columbia University; New York, USA 4. Socioeconomic Status And Disease Progression In Dominantly Inherited Alzheimer’S Disease María Florencia Clarens. Fleni; Argentina |
| 10:00 AM | Coffee Break & Networking |
| 10:30 AM | Symposium 1. Lessons Learned from Clinical Trials in ADAD & DSAD Moderators: Michael Rafii and Natalie Ryan · ALADDIN: Amyloid Lowering for Alzheimer’s in Down’s with Donanemab Investigation Zinayida Schlachetzki. USC Epstein Family Alzheimer’s Therapeutic Research Institute; California, USA · Post-mortem drug binding studies that he has done with sAD and DSAD Jasmeer Chhatwal. Harvard Medical School; Massachusetts, USA · Alzheimer’s Prevention Initiative-Colombia (API-Colombia) David Aguillón. Grupo de Neurociencias de Antioquia; Antioquia, Colombia |
| 12:00 PM | Oral Session 2. Clinical and Neuropsychological Moderators: Jason Hassenstab and Sigan Hartley 1. Designing A Reserve And Lifestyle Assessment For People With Down Syndrome (RLS-DS): An ISTAART-Led Initiative Lidia Vaqué-Alcázar. Hospital of Sant Pau; Barcelona, Spain 2. Trajectories Of Cognitive Functioning In Adults With Down Syndrome Based On Residence Dasoo Milton Yoon. University of Wisconsin-Madison; Wisconsin, USA 3. Epilepsy In Adults With Down Syndrome: A Multicentre Clinical Study Lucia Maure-Blesa. Hospital of Sant Pau; Barcelona, Spain 4. Survival After Alzheimer’s Dementia Diagnosis In Down Syndrome: The Role Of Genetics, Care And Clinical Factors Eimear McGlinchey. Trinity College Dublin; Dublin, Ireland |
| 1:30 PM | Lunch and Poster Session 1 (even-numbered posters) Moderators: María Carmona and Neus Falgàs |
| 3:00 PM | Keynote: Colombia ADAD cohort Moderator: Raquel Sánchez-Valle David Aguillón. Grupo de Neurociencias de Antioquia; Antioquia, Colombia |
| 4:00 PM | Symposium 1: What is genetically determined Alzheimer’s disease? Should we consider including new forms? Moderators: Raquel Sánchez-Valle and Alberto Lleó Speakers: · John Hardy. UCL; London, UK. · Juan Fortea. Hospital of Sant Pau; Hub Alzheimer Barcelona Barcelona, Spain. |
| 4:30 PM | The Lancet perspective · Beatriz Gómez Pérez-Nievas. The Lancet; London, UK · Morgane Boillot. The Lancet Neurology; Valencia, Spain |
| 5:00 PM | End of Day 1 |
| April 10th, 2026 | |
|---|---|
| 8:30 AM | Oral Session 3. Fluid Biomarkers Moderators: Daniel Alcolea and Mircea Balasa 1. The Interactive Role Of Apoe And Sex In Down Syndrome Alzheimer’S Disease Julie Wisch. Washington University Medical School; St. Louis, USA 2. Nulisa Blood Based CNS Biomarker Panel Across The Adult Lifespan Of Down Syndrome Beau Ances. Washington University in Saint Louis; St. Louis, USA 3. Cerebrospinal Fluid Proteomic Profiling And Biomarker Discovery In Autosomal Dominant Alzheimer’s Disease Laura Ibáñez. Washington University School of Medicine; St. Louis, USA 4. Proteomic Profiling Of Cerebrospinal Fluid And Plasma In Autosomaldominant Alzheimer’s Disease Aina Comas-Albertí. Hospital Clínic de Barcelona; Barcelona, Spain |
| 10:00 AM | Symposium 2. Making Research Participation Meaningful: Perspectives of Adults with ADAD and Their Family Members Moderators: Sarah Walter and Beatriz Bosch |
| 11:00 AM | Coffee Break & Networking |
| 11:30 PM | Oral Session 4. Neuroimaging and Emerging Biomarkers Moderators: Beau Ances and Alexandre Bejanin 1. Distinct Temporal Patterns Of Tau Pet And Plasma Biomarkers In Autosomal Dominant Alzheimer’s Disease Mariola Zapater Fajarí. Karolinska Institutet; Solna, Sweden 2. Concordance Of Biological And Clinical Staging In Down Syndrome Associated Alzheimer’s Disease Jason Russell. Epstein Family Alzheimer’s Therapeutic Research Institute; California, USA 3. Plasma Phospho-tau217 Correlates With Amyloid And Tau PET Measures In People With Down Syndrome Zinayida Schlachetzki. USC Epstein Family Alzheimer’s Therapeutic Research Institute; California, USA 4. Resting-state fMRI in individuals with Down Syndrome, with or without Alzheimer’s Disease: a Systematic Review Leda Bianchi. King’s College London; London, UK |
| 1:00 PM | Lunch and Poster Session 2 (odd-numbered posters) Moderators: María Carmona and Neus Falgàs |
| 2:00 PM | Symposium 3. Perspectives from Latin America. Focus: Research capacity, care models, and trial readiness Moderators: Sid O’Bryant and Natalia Vilor · Down syndrome and Alzheimer’s disease Agustín Ibáñez. Global Brain Health Institute, Trinity College Dublin; Dublin, Ireland · Genetic Alzheimer’s disease work from ReDLat Carolina Ochoa. BrainLat Institute UAI, Universidad Adolfo Ibáñez; Santiago, Chile · LATAM FINGERS Lucia Crivelli. Fleni; Argentina · Social epigenetics Hernando Santamaría-García. Universidad Javeriana; Bogotá, Colombia |
| 3:30 PM | Symposium 4. Making Research Participation Meaningful: Perspectives of Adults with DSAD and Their Family Members Moderators: Isabel Barroeta and Eimear McGlinchey |
| 4:00 PM | Life Achievement Award Presenters: Juan Fortea and Raquel Sánchez-Valle · DSAD: Down syndrome and Alzheimer disease: a neurological perspective Ira Lott. University of California; Irvine, USA · ADAD: Faltering steps towards mechanistic therapies in neurodegenerative diseases John Hardy. University College London; London, UK |
| 5:30 PM | Closing Remarks Maria Carrillo, Raquel Sánchez-Valle and Juan Fortea |
* Sessions are listed in Central European Standard Time (CEST). Schedule is current at the time of posting